Post hoc path analysis of 79 patients with treatment-resistant depression given 25 mg psilocybin: pre-dosing therapeutic alliance had no nominally significant direct effect on week-3 MADRS change but was linked to the psychedelic experience, which related more to outcome.
Secondary analysisn = 79
Goodwin et al. The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis